HER2

Explore the complexities of HER2 research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against HER2 with flcube.com.

FDA Approves AbbVie's Tavapadon as Juvmo for Parkinson's Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfoli
CompanyDrug

FDA Approves AbbVie’s Tavapadon as Juvmo for Parkinson’s Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfolio

The US Food and Drug Administration (FDA) announced that it has approved AbbVie's (NYSE: ABBV) tavapadon for the treatment of Parkinson's disease, under the brand name Juvmo. Regulatory Milestone ItemDetailAgencyUS…

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers

Biokin's BL-M12D1 Wins NMPA Clinical Trial Approval – ADC Candidate to Be Evaluated as Monotherapy in Relapsed or Refractory Hematologic Malignancies

Biokin’s BL-M12D1 Wins NMPA Clinical Trial Approval – ADC Candidate to Be Evaluated as Monotherapy in Relapsed or Refractory Hematologic Malignancies

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Jiangsu Hengrui's Trastuzumab Rezetecan on Track for NMPA's Breakthrough Therapy Designation
CompanyDrug

Jiangsu Hengrui’s Trastuzumab Rezetecan on Track for NMPA’s Breakthrough Therapy Designation

Merus N.V. Receives FDA Approval for Bizengri for NRG1+ Pancreatic and Lung Cancers
CompanyDrug

Merus N.V. Receives FDA Approval for Bizengri for NRG1+ Pancreatic and Lung Cancers

Shanghai Henlius Biotech's HLX22 Receives NMPA Approval for Phase II HER2-Targeted Study
CompanyDrug

Shanghai Henlius Biotech’s HLX22 Receives NMPA Approval for Phase II HER2-Targeted Study

Henlius Pharmaceutical Initiates Phase III Study for HLX22 in Gastric Cancer Treatment
CompanyDrug

Henlius Biotech Initiates Phase III Study for HLX22 in Gastric Cancer Treatment

Sichuan Biokin Pharmaceutical Gets FDA Approval for Phase I Study of BL-M17D1 in Solid Tumors
CompanyDrug

Sichuan Biokin Pharmaceutical Gets FDA Approval for Phase I Study of BL-M17D1 in Solid Tumors

Alphamab Oncology
CompanyDeals

Jiangsu Alphamab Biopharmaceuticals Partners with Shanghai Jinmant Biotech for JSKN003 ADC

CompanyDeals

Alphamab Oncology Strikes Licensing Deal with CSPC Pharma for HER2 Targeted ADC in China

Drug

FDA Panel Weighs in on Narrowing Use of PD-1 Inhibitors in Stomach and Esophageal Cancers

Show More